eli lilly lawsuit tirzepatide update Zepbound [2026] Eli Lilly files complaint with

Most clinical trial participants started at 2mg per week as the initial dose, with planned escalation over the following months

Ideal Candidate: Targeted Stubborn Fat: Individuals with small, localized fat pockets that do not respond to healthy lifestyle habits, rather than those seeking major weight loss

Jump to: Comparison at a glance | Tirzepatide (Mounjaro) | Semaglutide (Wegovy) | Liraglutide (Saxenda) | NHS vs private access | Side effects comparison | Cost analysis | How to choose | Medications in development | Frequently asked questions | Take home message Based on clinical trial data, the most effective weight-loss injection available in the UK in 2026 is tirzepatide (Mounjaro), with an average weight loss of 22.5% of starting body weight after 72 weeks at the maximum 15 mg dose

During the early weeks, lower doses help reduce the likelihood of gastrointestinal side effects, such as nausea or constipation

Third treatment didnt relieve my symptoms either